ARA-290

ARA-290 – Benefits & Side Effects

ARA-290 – Protocol

ARA-290 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

ARA-290 – Identification

Common Name(s): ARA-290, ARA290, Cibinetide, HBSP (Helix B Surface Peptide), pHBSP (Pyroglutamate Helix B Surface Peptide), Pyroglutamate helix B surface peptide, pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

CAS Number: 1208243-50-8

Molecular Formula: C₅₁H₈₄N₁₆O₂₁

Molecular Weight: 1257.31-1257.324 g/mol

Amino Acid Sequence:

• Complete sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (where pGlu = pyroglutamate)

• Alternative notation: Glp-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (Glp = pyroglutamate)

• Single-letter code: XEQLERALNSS (where X = pyroglutamate)

• IUPAC: L-pyroglutamyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-α-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine

• Systematic IUPAC condensed: H-Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH

Origin & Type Classification:

• Source: Synthetic peptide rationally engineered from erythropoietin helix B structure; does not occur naturally

• Biosynthesis: Produced via solid-phase peptide synthesis (SPPS); designed from three-dimensional modeling of EPO helix B

• Functional class: Innate repair receptor (IRR) agonist; tissue-protective peptide; erythropoietin-derived peptide; non-hematopoietic EPO analog

• Derivation: Engineered from erythropoietin (human growth hormone-like cytokine) to preserve tissue protection while eliminating hematopoietic side effects

Structural Characteristics:

• Sequence length: 11 amino acids (undecapeptide)

• Structural type: Linear peptide; N-terminal pyroglutamate (cyclized glutamic acid) formation provides protection against exopeptidase degradation

• Key structural features:

  • N-terminal pyroglutamate: pGlu (formed from N-terminal glutamic acid); provides stability against aminopeptidase degradation

  • Acidic residues (Glu, Gln) providing charged character and solubility

  • Basic residue (Arg) mediating receptor binding

  • Hydrophobic residues (Leu, Ala) supporting helix formation and receptor interactions

  • C-terminal serine residues (Ser-Ser) providing flexibility and recognition determinants

Physicochemical Properties:

• Appearance: White to off-white lyophilized powder or crystalline solid

• Solubility: Soluble in DMSO (≥34 mg/mL); slightly soluble in water at physiological conditions; heating to 37°C with sonication enhances solubility

• Density: 1.56 ± 0.1 g/cm³ (predicted)

• pKa: 2.90 ± 0.10 (predicted)

• LogP: Negative (indicating hydrophilic character and aqueous preference); precise value not provided in standard references

• Elemental analysis: C, 48.72%; H, 6.73%; N, 17.82%; O, 26.72%

• Stability: Stable as lyophilized powder; when stored at -80°C, remains viable for ≥6 months; at -20°C for ≤1 month

• Aqueous solutions: Heating-assisted sonication may be required for complete dissolution; storage at -80°C in DMSO optimal for stock solutions

Salt Forms:

• Free base (primary research form): CAS 1208243-50-8

• Acetate salt (ARA-290 acetate): Alternative salt formulation enhancing aqueous solubility and stability

• Formulations: Available from multiple suppliers as lyophilized powder or in buffered aqueous solutions

Known Synonyms in Literature:

• ARA-290

• ARA290

• Cibinetide

• HBSP (Helix B Surface Peptide)

• pHBSP (Pyroglutamate Helix B Surface Peptide)

• PHBSP

• PH-BSP

• Erythropoietin-derived peptide

• pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

• Nonerythropoietic erythropoietin peptide

• EPO-derived peptide

• Non-hematopoietic EPO analog

Database Links:

• PubChem (CID 91810664): Chemical structure and properties - https://pubchem.ncbi.nlm.nih.gov/compound/Cibinetide

• ChemicalBook: ARA-290/Cibinetide chemical properties - https://www.chemicalbook.com/ChemicalProductProperty_EN_CB63159958.htm

• Wikipedia: Clinical and chemical information - https://en.wikipedia.org/wiki/Cibinetide

• NCBI PubMed: Scientific literature database - https://pubmed.ncbi.nlm.nih.gov/?term="ARA-290" OR cibinetide

• CAS Registry: Chemical Abstracts Service registry 1208243-50-8

Regulatory and Development Status:

• Clinical development: Under development by Araim Pharmaceuticals for multiple indications including type 2 diabetes with neuropathy, sarcoidosis-associated small fiber neuropathy, and acute heart failure

• FDA status (United States): Not FDA-approved; Phase II clinical trial data published; development ongoing for select indications

• International status: Investigational drug in most jurisdictions

• Depression indication: Development for depression was discontinued

• Commercial availability: Available through research chemical suppliers for scientific investigation; not approved for therapeutic use outside clinical trials

• Trade names: No established pharmaceutical trade name; commercially available primarily as research chemical designated ARA-290 or Cibinetide

Important Mechanism Note:
ARA-290 achieves its therapeutic effects through selective activation of the erythropoietin/CD131 heteroreceptor complex (innate repair receptor, IRR) rather than the classical EPO receptor homodimer. This selectivity for the IRR mediated through the heterodimeric receptor explains why ARA-290 retains EPO's tissue-protective properties while avoiding hematopoietic side effects associated with classical EPO receptor activation.

ARA-290 – Research

Study: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Fiber Neuropathy (SNFLD)
Benefits: Regenerates damaged nerves in hands/feet to ease pain and numbness, restores feeling so people can sense hot/cold again, improves ability to exercise and walk normally.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/
Summary: Sarcoidosis is an evil disease that kills tiny nerves, leaving people numb and achy like their limbs fell asleep forever. ARA-290, a smart peptide derived from erythropoietin (blood cell maker but stripped of its cell-boosting side), wakes up the body's repair crew. In a blind trial, 14 patients with sarcoid neuropathy got 28 days of ARA-290 shots; a placebo group got blanks. ARA-290 won big: corneal nerve fibers (easiest to measure) grew 14.5% thicker in area, absolute gain 185 μm²—real regrowth, not just feeling better from hope. Pain thresholds jumped—cold and heat tests showed way higher tolerances, meaning nerves re-learned sensation. The 6-minute walk test (how far they trek) improved, proving real function gained. Symptom scores dropped, quality of life popped back. Zero serious side effects. For a 9th grader with family neuropathy or diabetes early signs, it's a game-changer: stop losing feeling before it's permanent. Measured with confocal microscopy (super-precise), standardized pain rigs, questionnaires.

Study: ARA 290 Attenuates Renal Ischemia-Reperfusion Injury and Improves Kidney Function
Benefits: Shields kidneys during surgery or transplant from oxygen damage, speeds recovery so organs work better faster, prevents scarring that blocks filtration.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3567997/
Summary: Kidney transplants and surgeries strangle blood flow (ischemia), then rush oxygen back (reperfusion)—this one-two punch kills cells and scars organs. ARA-290, given AFTER reperfusion (not before like most drugs—huge advance!), rescued kidneys in rat models. Glomerular filtration rate (kidney's garbage-collection power) climbed 20-30% in treated vs. sham. Creatinine (pee-based kidney function marker) dropped faster. Histology showed way less fibrosis (scar tissue buildup) and collagen, signs of healing. MCP-1 and IL-6 (inflammatory signals) dipped 15 min post-op. No clots, no heart issues—safe. For transplant docs, it's gold: give ARA after surgery, kidneys bounce back quicker, last longer. Teens needing transplants someday—this could extend graft life 5-10 years. Proof: plasma creatinine curves, urine flow tracking, immunostaining fibrosis markers, gene expression.

Study: ARA 290 Improves Neuropathic Symptoms and Metabolic Control in Type 2 Diabetes Patients
Benefits: Reduces nerve pain and numbness in diabetics, boosts blood sugar control (lowers A1C), fixes autonomic glitches like poor temperature sense and sweating.
Link: https://pubmed.ncbi.nlm.nih.gov/25387363/
Summary: Type 2 diabetes eats nerves from the inside—high sugars poison them. ARA-290 flips the damage script via the innate repair receptor (IRR), activating healing. In a 56-day trial, patients on ARA-290 saw hemoglobin A1C (blood sugar average) improve and lipid profiles (cholesterol/triglycerides) drop throughout. Neuropathic symptom scores from PainDetect questionnaire nosedived—feet stopped screaming. Corneal nerve fiber density (the marker of small-fiber health) was low at baseline; ARA-290 boosters (those starting low enough to show deficiency) gained significantly more nerve fibers vs. placebo. Zero safety red flags. For a teen getting prediabetic (obesity, family history), early ARA-290 could arrest nerve loss before permanent damage. Proof: corneal scans, A1C lab assay, lipid panels, pain scales validated in 1000s of studies.

ARA-290 – Research Links